

Space for Sustainable Pharma

ESA Webinar

Beatrice Barresi: Beatrice.barresi@esa.int

Manon Houyet: Manon.houyet@esa.int


20/09/2024



Welcome to the Webinar!

Before we start...

- Please keep your microphones muted during the webinar and make sure your webcam is switched off.
- You can use the conversation function anytime to submit your questions. They will be addressed during the Q&A at the end of the webinar



Agenda



ESA Welcome and Introduction

About ESA's Space for Sustainable Pharma competition

Sustainability in the pharmaceutical industry and **Space**


How to Apply to the competition

Q&A Session





The European Space Agency





EUROPE'S GATEWAY TO SPACE

WHAT

22 Member States, 5000 employees

WHY

Exploration and use of space for exclusively peaceful purposes

WHERE

HQ in Paris, 7 sites across Europe and a spaceport in French Guiana

HOW MUCH

€6.49 billion = €12 per European per year





Business Applications: space-enabled services



BASS aims at reaching commercial exploitation of space assets, data and capabilities addressing

technical feasibility and business development.

This includes the development of operational services for a wide range of users through the combination of different systems, and support in creating viable companies as well as to existing companies



What can BASS offer to companies?









Zero-equity funding (from €50k to €2M+ per activity)



A personalised ESA consultant



Technical support and commercial guidance



Tailored project management support



Access to our international network of ESA and partners




Access to our network of investors



Credibility of the ESA brand

Sustainability elements of space applications





Sustainable applications with green impact




It is estimated that abandoning the current high-carbon pathway in favour of a low-carbon future will bring €26 trillion in economic benefit.

Investment in BASS Green Activities since 2010

Market demand for green solutions, new ESA BASS funding opportunities, and collaborations with industry partners will support future growth in sustainable development investment

With €183M invested into
300 ideas the green transition now drives
48% of all new ESA Space Solutions.





Background: Pharmaceutical sector

esa

- The pharmaceutical sector is crucial for improving human and animal health.
 - Cure diseases.
 - Neutralize symptoms.
 - Delay the onset of diseases.
- →Boosting life expectancy and quality of life.
- But impact on the environment:
 - Polluting the air, water and soils.
 - AMR: Impact the health of others negatively.
 - → API require proper disposal.
 - Waste creation: Drug packaging.
- Reaction from WHO, EFPIA, UNEP and EEB to promote the implementation of circular economy in pharma to tackle those challenges.







Disposal of unused & expired medicine.



Digital Twin for sustainable pharma.



Circularity in the pharmaceutical industry.

Topics of relevance: Disposal of unused & expired medicine




Problem description:

- Waste generation:
 - In the UK, yearly, 354 million EUR.
 - In France, in 2018, 260kg/ capita.
 - In general, 3-8% of the sold drugs.
- Wrong disposal leads to AMR.

Solutions: Decrease number of drugs thrown away.

- Just-in-Time approach.
- Efficient logistics.
- Collection of expired medicines.
- Raise citizens' awareness.



Topics of relevance: Digital Twin for sustainable pharma



Digital Twin (DT) has many advantages as it enables to deploy and prove solutions faster and at a lower cost, reducing risks, etc. This can also be used for the pharmaceuticals.

1. Operation management:

- Reduce the environmental impact of manufacturing process of pharmaceuticals.
- Shift to renewable energy: comparing different renewable energy systems.
- Assessment of machinery conditions to maximized their lifespan.

2. Drug development:

- Time-consuming and expensive.
- Influences 80% of the environmental impact a drug will have.
- Reduces the risk of testing, cuts down the cost of development process and optimizes processes while minimizing the impact on the environment

3. Personalized medicines:

- Optimal treatment: optimal drug and dosage choice.
- Real-time data from sensors combined to clinical DT.



Topics of relevance: Circularity in pharmaceutical industry




Each kg of medicine = 100 kg of waste. **Circular pharma**, therefore, aims to minimize waste creation throughout the whole life cycle of medicines and promotes recyclability.

1. Water recycling:

- APIs are discharged through urine, contaminating water and soils.
- Address the impact of pharma on water both during chemistry/ production process and after excretion.

2. Machinery recycling:

- In 2023, pharma manufacturing equipment was worth 14.5
 billion USD. Rapidly outdated.
- Solutions: Monitoring the machines conditions the aim to optimize their life expectancy, collection of outdated equipment and the development of recycling techniques.
- **3. Packaging recycling:** focuses both on the collection of contaminated packaging and sustainable purifying solutions before recycling.



Value-added of space



Disposal of unused & expired medicine

JIT

Awareness

campaigns in

remote locations

Environmental impact assessments



Collection of expired drugs



DT for sustainable pharma

Connection of insitu sensors



Operation management: Renewable energy predictions



Environmental impact of drug development



Circularity in the pharmaceutical industry

Monitoring of disease spread & water quality (WWTPs)



-

Drones for WWTPs inspection



Efficient collection routes

Monitor performance

of manufacturing

equipment





Who can apply?

To be eligible for funding, your team must be based in one of the following countries:

Belgium, Czech Republic, Denmark, Estonia, Finland, France, Germany, Hungary, Ireland, Italy, Lithuania, Luxembourg, The Netherlands, Norway, Poland, Portugal, Romania, Slovenia, Sweden, Switzerland and United Kingdom.

If you are considering applying, you must inform your National Delegation to obtain a letter of authorisation allowing the funding of the proposed activity. Contact details of each National Delegate can be found here: https://business.esa.int/national-delegations-0

However, if your team is based in **Germany, Luxembourg, Slovenia, and the United Kingdom** you do not have to contact your National Delegate.



How to apply?

- Register your team on esa-star Registration today! https://esastar-emr.sso.esa.int
- 2. On the 23rd September 2024 visit esa-star Publication and search for this opportunity to download the official competition documents. https://esastar-publication.sso.esa.int
- 3. Use the official documents to prepare your proposal
- 4. Contact details of each National Delegate can be found here: https://business.esa.int/national-delegations-0
- 5. Submit your proposal via esa-star Tendering by the 3rd of November 2024. https://esastar.sso.esa.int

Opening dates: 23rd September – 3rd November 2024



Space for Sustainable Pharma: about the Kick-Start Activity



Winners of the competition will run a 6-month study to investigate the technical feasibility and commercial viability of their idea.

Kick-Start activities are funded at 75% by the European Space Agency for a maximum of €75K per contract.

After the study there is the opportunity for further funding and support from ESA.

Visit: Space for Sustainable Pharma (esa.int)






































Overall Aim of the Kick-Start Activity





A UNCLASSIFIED - FOR ESA UTICIAI USE UTILY



